Drug
Mecapegfilgrastim
Mecapegfilgrastim is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
2(50%)
Phase Distribution
Ph phase_2
3
75%
Ph not_applicable
1
25%
Phase Distribution
0
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Other(1)
Detailed Status
Active, not recruiting1
Not yet recruiting1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2
Trials by Phase
Phase 23 (75.0%)
N/A1 (25.0%)
Trials by Status
active_not_recruiting125%
not_yet_recruiting125%
recruiting125%
unknown125%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_2
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05076682
active_not_recruitingphase_2
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
NCT05463601
not_yet_recruitingphase_2
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT06684158
unknownnot_applicable
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
NCT04171986
Clinical Trials (4)
Showing 4 of 4 trials
NCT05076682Phase 2
Reverse Triple Negative Immune Resistant Breast Cancer
NCT05463601Phase 2
Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer
NCT06684158Phase 2
Mecapegfilgrastim Combined With Adebrelimab and Chemotherapy as Neoadjuvant Therapy in Resectable GC/GEJC
NCT04171986Not Applicable
Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4